Product Liability — Federal Rules for Defective Products & Consumer Safety

Product liability is the area of law holding manufacturers, distributors, and retailers legally responsible when a defective product causes injury. While product liability is primarily governed by state tort law (each state has its own rules), federal law plays a critical role through safety regulations (CPSC, FDA, NHTSA, CPSIA), federal preemption (determining when federal safety standards override state tort claims), multidistrict litigation (MDL — consolidating thousands of product liability cases in a single federal court), and class action jurisdiction (CAFA — the Class Action Fairness Act moves large product liability class actions to federal court). Product liability claims can be based on three theories: manufacturing defect (the product deviated from its intended design), design defect (the product's design is inherently dangerous), and failure to warn (the product lacked adequate warnings or instructions). Under strict liability — adopted in most states following the Restatement (Second) of Torts § 402A (1965) — a manufacturer can be liable for a defective product regardless of fault: you don't need to prove the manufacturer was negligent, only that the product was defective and caused your injury. Major product liability litigation has shaped American consumer safety: asbestos (the largest mass tort in history), tobacco, opioids, Roundup (glyphosate), 3M earplugs, talcum powder, and PFAS ("forever chemicals") — each involving tens of thousands of claims and billions of dollars.

Current Law (2026)

Legal Authority

• Restatement (Third) of Torts: Products Liability (1998) — influential (but not binding) framework adopted by many state courts
• 15 U.S.C. §§ 2051–2089 — Consumer Product Safety Act (CPSC authority to set safety standards and order recalls)
• 28 U.S.C. § 1407 — Multidistrict Litigation (MDL) — consolidation of product cases
• 28 U.S.C. § 1332(d) — Class Action Fairness Act (CAFA) — federal jurisdiction for large class actions
• Preemption cases: Riegel v. Medtronic (2008), Wyeth v. Levine (2009), Mutual Pharmaceutical v. Bartlett (2013)

How It Works

Product liability law recognizes three defect theories. A manufacturing defect exists when a specific product deviates from its intended design — a car with a misinstalled brake line, a food product contaminated during processing. The design is fine; this particular unit went wrong. A design defect exists when the entire product line is unreasonably dangerous — all units are defective because the design itself creates an excessive risk. Courts use either the consumer expectations test (was the product more dangerous than an ordinary consumer would expect?) or the risk-utility test (do the risks of the design outweigh its benefits?). A failure to warn exists when the product lacks adequate warnings or instructions about known risks — even if it is properly designed and manufactured. The most consequential federal product liability question is preemption: when a product complies with federal safety standards, can injured consumers still sue under state tort law? The answer varies dramatically by product type. For Class III medical devices receiving FDA premarket approval (PMA), Riegel v. Medtronic (2008) held that state tort claims are preempted — if the FDA approved the device, states can't impose different requirements. For brand-name prescription drugs, Wyeth v. Levine (2009) held the opposite — FDA approval does not preempt state failure-to-warn claims, because manufacturers can always add stronger warnings. For generic drugs, Mutual Pharmaceutical v. Bartlett (2013) held that generic manufacturers cannot be sued for design defect or failure to warn because they must match the brand-name formulation and labeling, so federal law preempts.

When a defective product injures thousands of people who file suits across the country, the Judicial Panel on Multidistrict Litigation (28 U.S.C. § 1407) can consolidate all cases before a single federal judge for pretrial proceedings. MDLs now account for over 70% of the federal civil docket; major product liability MDLs include opioids (2,500+ cases), Roundup/glyphosate ($10+ billion in settlements), 3M military earplugs (300,000+ claims), and PFAS water contamination. Plaintiffs can recover compensatory damages (medical expenses, lost wages, pain and suffering) and, in many states, punitive damages for egregious misconduct. The largest product liability outcome remains the tobacco Master Settlement Agreement (1998) — $206 billion over 25 years.

How It Affects You

If you've been injured by a product: Under strict liability — the standard in most states — you don't need to prove the manufacturer was negligent. You need to show the product was defective (manufacturing defect, design defect, or failure to warn), the defect caused your injury, and you were using the product as intended (or in a reasonably foreseeable way). Immediately preserve the defective product and packaging as evidence; photograph your injuries; document the purchase (receipt, delivery confirmation, credit card statement); and seek prompt medical attention with documentation linking the injury to the product. The statute of limitations for product liability claims is typically 2–4 years from the injury or discovery of harm — consult an attorney promptly, especially for latent injuries (like cancer from chemical exposure) where the clock may run from when you knew or should have known the product caused harm, not the original exposure.

If you're a product manufacturer or retailer: Federal safety regulatory compliance (CPSC standards, FDA approvals for medical devices, NHTSA standards for vehicles) does not automatically protect you from state product liability tort claims — preemption is product-category-specific and fact-specific. For FDA-approved Class III medical devices, Riegel v. Medtronic (2008) provides broad preemption of state tort claims challenging the approved design. But for FDA-approved drugs, Wyeth v. Levine (2009) found minimal preemption — FDA approval doesn't bar state failure-to-warn claims. Maintain comprehensive product testing records, failure mode analyses, and post-market surveillance data; these are your primary defense in litigation and evidence of adequate design and warning. The cost of quality control is small relative to the cost of a single mass tort MDL.

If you believe a defective product has harmed many people: The MDL (Multidistrict Litigation) system consolidates thousands of similar product liability cases from across the country before a single federal judge for pretrial proceedings. If you have a claim against a company involved in an active MDL (opioids, PFAS "forever chemicals," Roundup, 3M earplugs, social media youth harm), check the MDL docket on PACER to see if a claims process or settlement has been established. Filing in your local federal court may trigger automatic transfer to the MDL; a plaintiff's attorney with MDL experience is valuable because the consolidated discovery and bellwether trials in MDLs drive most settlements. Many mass tort MDLs settle via global resolution agreements with claims administrators — watch for announcements about settlements in your product's MDL.

If you're considering a product liability claim involving an FDA-regulated drug or medical device: Preemption law distinguishes between brand-name and generic drugs. For brand-name drugs, state tort failure-to-warn claims generally survive federal preemption (Wyeth v. Levine). For generic drugs, the manufacturer cannot change the warning label independently — it must match the brand-name label — so state failure-to-warn claims are largely preempted (PLIVA v. Mensing 2011, Mutual Pharmaceutical v. Bartlett 2013). This creates the counterintuitive result that injured patients who took a generic drug may have fewer legal remedies than those who took the brand-name equivalent — a significant policy debate in pharmaceutical tort law that has not been legislatively resolved as of 2026.

State Variations

Product liability is primarily state law — significant variation:

• Strict liability: Most states follow some form; a few (Delaware, Michigan, North Carolina, Virginia) still require negligence proof
• Comparative fault: Most states reduce damages by the plaintiff's percentage of fault; a few pure contributory negligence states bar recovery entirely if the plaintiff was at fault
• Statutes of limitation: Typically 2–4 years from injury discovery; statutes of repose (6–12 years from sale) may bar older claims regardless of discovery
• Punitive damages: Available in most states but capped in many (e.g., Texas, California, Ohio)
• Government contractor defense: Some states recognize immunity for products manufactured to government specifications

Implementing Regulations

Product liability in the U.S. is primarily state tort law; there is no comprehensive federal product liability statute. Federal regulations that affect product liability include:

• 16 CFR Part 1115 — Substantial Product Hazard Reporting (CPSA Section 15(b)): the CPSC's implementing rules for the mandatory reporting obligation that requires manufacturers, importers, distributors, and retailers to notify CPSC when they obtain information indicating a product may present a substantial product hazard. Key provisions:

  • § 1115.2 — What is a "substantial product hazard": two distinct triggers exist — (1) a failure to comply with an applicable CPSC safety rule that creates a substantial risk of injury; or (2) a product defect (whether or not covered by a safety rule) that creates a substantial risk of injury to the public; the second category — unreasonable risk from a defect even without a rule violation — is the broader and more commonly triggered reporting obligation
  • § 1115.10 — Who must report: every manufacturer (including importer), distributor, or retailer of a consumer product distributed in commerce who obtains information that the product contains a defect that could create a substantial product hazard must report to CPSC; the obligation runs to all three distribution-chain participants, not just the manufacturer
  • § 1115.11 — Imputed knowledge: the reporting obligation attaches when information is received by any official or employee in a position to take action on safety information — a company cannot escape its reporting timeline by claiming the safety-relevant information was received by a low-level employee and not communicated to senior management; CPSC evaluates whether a "reasonable and diligent" organization would have escalated the information
  • § 1115.12 — When to report; evaluating substantial hazard: firms should not delay reporting to achieve certainty about the hazard — the obligation triggers when the firm has "reasonably supported information" suggesting a reportable condition; CPSC does not require the firm to have completed an investigation; evaluation factors include: pattern of failures, severity of potential injury, number of products in commerce, and probability that the defect will actually cause injury; reports must be filed within 24 hours of obtaining information sufficient to conclude a reportable condition exists (or could reasonably exist)
  • § 1115.13 — Content and form of reports: initial reports may be oral or written; the CEO or designated official must sign written reports; initial reports must identify the product, the nature of the defect or noncompliance, the incident/injury history, and any remedial action planned or taken; CPSC staff will conduct follow-up investigation
  • § 1115.15 — Confidentiality: reports are not routinely made public until CPSC staff has made a preliminary hazard determination; companies can argue that information constitutes trade secrets — but CPSC's track record is that safety-relevant information will ultimately be disclosed in the context of recalls or corrective action
  • §§ 1115.20–1115.21 — Voluntary vs. compulsory remedial action: after receiving a report, CPSC will seek voluntary remedial action — corrective action plans, recall notices, product replacement or refund programs — before pursuing compulsory orders; the vast majority of CPSC product recalls are voluntary, negotiated between CPSC staff and the firm; compulsory Commission orders are reserved for firms that fail to cooperate voluntarily; recall notices must meet specific format and content requirements under Subpart C (§§ 1115.23+)
  • § 1115.22 — Penalties: knowingly violating the reporting requirements under CPSA § 15(b) can result in civil penalties up to approximately $137,395 per violation (2025 levels held for 2026 per OMB M-26-11), with maximum penalties for a related series of violations capped at approximately $20.4 million; criminal penalties (fines and imprisonment) apply for willful falsification or concealment of material facts in required reports

  The 24-hour reporting window and the imputed knowledge doctrine (§ 1115.11) create the central compliance challenge: companies must have systems for rapidly identifying and escalating product safety signals — customer complaints, warranty claims, personal injury litigation, foreign regulatory actions, and internal testing failures — to the executives responsible for Section 15 compliance. Large consumer products companies typically have "Section 15 committees" that review incoming safety information on a regular cadence. Failure to report in time has resulted in some of CPSC's largest civil penalties: Peloton ($19.1 million), IKEA ($46 million), and Samsung ($1.37 million) are recent examples of substantial Section 15 enforcement actions.

• 49 CFR Part 573 — NHTSA defect and noncompliance reports, requiring motor vehicle and equipment manufacturers to submit early warning reports and recall notifications for safety defects

• 21 CFR Part 803 — FDA Medical Device Reporting, requiring manufacturers, importers, and device user facilities to report adverse events involving medical devices that have caused or could cause serious injury or death

Pending Legislation

Federal product liability reform and tort reform bills are periodically introduced. See Consumer Product Safety for related legislative activity in the 119th Congress.

Recent Developments

Product liability litigation continues to drive massive legal and financial consequences. The opioid MDL has generated over $50 billion in settlements from manufacturers, distributors, and pharmacies. PFAS ("forever chemicals") litigation is expanding rapidly — targeting manufacturers and water utilities for contamination affecting millions of Americans. Social media youth harm litigation (alleging design defects in addictive platform features) represents a new frontier in product liability theory. The Supreme Court continues to refine preemption doctrine — the distinction between preempted and non-preempted claims remains one of the most consequential issues in product liability law.